Jazz Pharmaceuticals JAZZ Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's stock-based comp?
- Jazz Pharmaceuticals (JAZZ) reported stock-based comp of $74.5M in Q1 2026.
- How has Jazz Pharmaceuticals's stock-based comp changed year-over-year?
- Jazz Pharmaceuticals's stock-based comp increased by 10.0% year-over-year, from $67.7M to $74.5M.
- What is the long-term trend for Jazz Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Jazz Pharmaceuticals's stock-based comp has grown at a 11.4% compound annual growth rate (CAGR), from $189.01M to $291.13M.
- What does stock-based comp mean?
- The cost of paying employees with company stock instead of cash.
- How do you interpret stock-based comp?
- Increasing levels may signal talent retention efforts but also potential shareholder dilution.
- How does stock-based comp compare across companies?
- Standard across high-growth and tech-heavy sectors; varies based on compensation philosophy.